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ABSTRACT
The dynamic balance of cellular sphingolipids, the sphingolipid rheostat, 
is an important determinant of cell fate, and is commonly deregulated in cancer. 
Sphingosine 1-phosphate is a signaling molecule with anti-apoptotic, pro-proliferative 
and pro-angiogenic effects, while conversely, ceramide and sphingosine are pro-
apoptotic. The sphingosine kinases (SKs) are key regulators of this sphingolipid 
rheostat, and are attractive targets for anti-cancer therapy. Here we report a first-
in-class ATP-binding site-directed small molecule SK inhibitor, MP-A08, discovered 
using an approach of structural homology modelling of the ATP-binding site of SK1 
and in silico docking with small molecule libraries. MP-A08 is a highly selective 
ATP competitive SK inhibitor that targets both SK1 and SK2. MP-A08 blocks pro-
proliferative signalling pathways, induces mitochondrial-associated apoptosis in a  
SK-dependent manner, and reduces the growth of human lung adenocarcinoma 
tumours in a mouse xenograft model by both inducing tumour cell apoptosis and 
inhibiting tumour angiogenesis. Thus, this selective ATP competitive SK inhibitor 
provides a promising candidate for potential development as an anti-cancer therapy, 
and also, due to its different mode of inhibition to other known SK inhibitors, both 
validates the SKs as targets for anti-cancer therapy, and represents an important 
experimental tool to study these enzymes.
INTRODUCTION
A number of sphingolipids, including ceramide, 
sphingosine and sphingosine 1-phosphate (S1P), are 
important signaling molecules controlling a diverse 
array of important cell processes [1]. S1P, in particular, 
has diverse cell signaling roles through its actions as 
both a ligand for a family of five S1P-specific G protein-
coupled receptors (named S1P1–5), as well as a modulator 
of a range of intracellular proteins [2–4]. S1P receptor-
mediated signaling most notably plays significant roles in 
immune cell trafficking and vascular integrity, while S1P 
in general confers pro-proliferative, pro-survival signaling 
[5]. Sphingosine and many ceramide species, however, 
are pro-apoptotic, modulating the activity of a range 
of enzymes involved in the control of cell survival [5]. 
Thus, the balance between the cellular levels of S1P and 
ceramide/sphingosine, the so-called sphingolipid rheostat, 
appears an important regulator of cell fate.
The cellular levels of the sphingolipids are 
controlled by an array of bidirectional metabolic 
pathways that are subject to complex spatial and temporal 
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regulation [1, 6]. Some of the most important regulators 
of this system are the sphingosine kinases (SKs), which, 
through their action of phosphorylating sphingosine 
to generate S1P, play a vital role in controlling the 
sphingolipid rheostat [1], and therefore, cell fate. Two 
SKs exist in mammals; SK1 and SK2, which catalyze 
the same reaction and share a high degree of sequence 
similarity. The two SKs share some redundant and related 
roles, but also appear to possess some different functions, 
probably due to their different subcellular localizations, 
with SK1 predominantly localized to the cytoplasm 
while SK2 is mainly localized at the nucleus and other 
organelles [7].
The SKs have been widely implicated in 
carcinogenesis. SK1 expression is elevated in a wide 
array of human solid cancers, with higher levels of SK1 
correlating with the severity of malignancy and shorter 
patient survival [8]. Similarly, SK2 was recently found to 
be elevated in human non-small cell lung cancer, with high 
expression levels correlated with poor patient survival [9]. 
Furthermore, a large number of studies have shown that 
targeting SKs has considerable potential as an anti-cancer 
strategy. For example, RNAi-mediated knockdown or 
inhibition of SK1 and SK2 has been widely demonstrated 
to induce apoptosis and enhance sensitivity to chemo- or 
radiation therapy of many different cancer cells [10, 11]. 
Similarly, genetic ablation of SK1 and SK2 in mice was 
found to reduce tumor growth in vivo in numerous cancer 
models [12–19]. This body of evidence has secured the 
SKs as promising therapeutic targets in cancer and has 
driven drug development to target the enzymes in a range 
of cancer models [10, 11].
Initial SK inhibitor development used 
molecules derived from sphingosine including L-threo-
dihydrosphingosine, N,N-dimethylsphingosine and N,N,N-
trimethylsphingosine. These compounds, however, have 
low specificity, with several important off-targets identified, 
such as protein kinase C, ceramide synthase and the 14–3-3 
pro-survival protein [11, 20]. Other inhibitors developed to 
more selectively target the sphingosine-binding pockets of 
SK1 and SK2 have been successful in blocking cancer cell 
growth and reducing tumor burden in animal models [2, 11]. 
Again, however, these second generation SK inhibitors 
also appear to have numerous off-targets, with the most 
commonly employed SK inhibitor in the last decade, SKI-II 
[21] recently shown to inhibit dihydroceramide desaturase 
[22] and also enhance signalling via the Nrf2 transcription 
factor in a SK-independent manner [23]. Similarly, the most 
commonly used SK2-selective inhibitor ABC294640 has 
been shown to also act as a direct antagonist of the estrogen 
receptor [24].
Notably, some high affinity sphingosine-competitive 
SK1 inhibitors developed recently have been controversial. 
Despite showing potent SK1 inhibition in vitro and 
decreases in S1P in cells, these inhibitors failed to induce 
apoptosis or show anti-neoplastic properties in vivo 
[25–27]. This has lead to the groups that developed 
these reagents to reach the contentious conclusion that 
SK activity is not required for tumor cell viability [26], 
despite the large body of evidence to the contrary. Notably, 
unlike other SK inhibitors or SK knockdown, these recent 
inhibitors failed to enhance cellular ceramide levels at low 
concentrations where SK1 was inhibited [25–27]. This 
suggests the similarity of these molecules to sphingosine 
may result in off-target inhibition of ceramide synthases 
which blocks ceramide generation and associated  pro-
apoptotic signaling.
Here we describe the discovery and characterization 
of a novel SK inhibitor, MP-A08, using a structure-based 
approach to target the ATP-binding pocket of SK1. Via 
this approach we both exploit the known divergence of 
the SK ATP-binding site from other kinases [28] and also 
overcome common off-target effects of sphingosine-like 
molecules. Characterization of MP-A08 demonstrated its 
high selectivity to SK1 and SK2 over other kinases, and 
importantly revealed its anti-neoplastic effects against a 
panel of cancer cell lines in vitro and also in human lung 
tumor xenografts in mice.
RESULTS
Modeling and validation of the ATP-binding 
pocket of SK1
Until recently there was no structural information 
available for SK1. Therefore, we employed homology 
modeling to predict the structure of the ATP-binding 
pocket of SK1 using the solved structures of two 
bacterial lipid kinases, DgkB [29] and YegS [30] that, 
while possessing little overall sequence similarity to 
SK1, do show some sequence similarity with residues 
proposed to contribute to ATP binding in SK1 [1, 28, 
31] (Supplementary Figure 1). In the model (Figure 1A), 
residues from all five regions highly conserved in the SKs 
(Motifs 1–5; Supplementary Figure 1) were involved 
in forming the ATP-binding pocket of SK1, with the 
79SGDGLMHE86 motif forming the centre of the pocket. 
To identify potential residues most important for ATP 
binding we next computationally docked ATP into the 
predicted SK1 ATP-binding pocket (Figure 1A). The 
docked ATP was predicted to form hydrogen bonds with 
multiple residues in Motifs 1 to 4 (Asn22, Thr54, Gly80, 
Asp81, Gly82, Leu83, Glu86 and Ser112) (Figure 1A). 
Additionally, Asp341 and Glu343 from Motif 5 were 
predicted to coordinate a magnesium ion, as inferred from 
similarity to the DgkB structure [29].
To validate the modeling and ATP docking we then 
carried out alanine mutagenesis of the residues predicted 
to contribute to the ATP-binding pocket. Mutagenesis 
of all the SK1 residues predicted to form hydrogen-
bonds with ATP either abolished or substantially reduced 
enzyme activity, while mutation of other residues in this 
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Figure 1: Structural modeling, analysis and virtual screening of the ATP-binding pocket of SK1. (A) The predicted 
structure of the ATP-binding pocket of SK1 represented in surface view with ATP docked into the pocket (sticks). Each of the regions highly 
conserved in all SKs (see Supplementary Figure 1) that comprise the ATP-binding pocket are colored separately; Motif 1 (21LNPRGG26) in 
teal, Motif 2 (54TERR57) in orange, Motif 3 (79SGDGLMHE86) in blue, Motif 4 (110GSGN114) in purple, and Motif 5 (340VDGE343) in yellow. 
The atoms in ATP are colored according to chemical elements; oxygen in red, and nitrogen in blue. Predicted hydrogen bonding is depicted 
by black dashes. (B) Mutagenesis of SK1 at residues predicted to be important in ATP binding and assessment of residual SK1 activity 
(upper panel) confirmed the validity of the SK1 ATP-binding site model. SK1 activities were determined after overexpression in HEK293T 
cells, and presented as % activity compared to wildtype SK1 (WT). Empty vector (EV) transfected cells show negligible contribution from 
endogenous SK to the activities displayed. The lower panel shows similar expression levels of all FLAG-tagged SK1 variants, but activities 
were adjusted for slight variations in expression. Data shown are mean ± SD, n = 4). Significance compared to WT was determined by 
student t-test (*p < 0.05, **p < 0.01 and ***p < 0.001). (C) The chemical structure of MP-A08. (D) The ATP binding pocket of the SK1 
model with MP-A08 docked. Coloring is the same as for Figure 1A, with yellow atoms representing sulphur. (E) Effect of MP-A08 (250 
μM) on the activity of SK1 variants harboring mutations in the ATP-binding site. Data are represented as % activity compared to vehicle 
control. All data shown are mean ± SD (n = 4), significance compared to SK1WT was determined by student t-test (*p < 0.05, **p < 0.01 
and ***p < 0.001). (F) Selectivity of MP-A08 (0.1 mg/ml, 192 μM) was initially assessed against human SK1, SK2, DAGK and CERK, 
and murine SK1 and SK2. Data are represented as % activity compared to vehicle control. All data shown are mean ± SD (n = 4).
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region not predicted to directly interact with ATP (Arg24, 
Glu55 and Ser79) generally had less effect (Figure 1B). 
Mutation of Asp341 and Glu343 abolished SK1 activity, 
consistent with their proposed role in the coordination 
of the magnesium ion cofactor. Together, these findings 
supported the accuracy of the model. Notably, the recent 
availability of the SK1 crystal structure [32] also enabled 
us to retrospectively assess the validity of our model. 
Structural alignment of the ATP-binding pocket residues 
of our SK1 ATP-binding site model with those of the 
ADP-bound SK1 crystal structure (3VZD) showed very 
close alignment (RMSD = 1.1366 Å), further confirming 
the validity of our model (Supplementary Figure 2). 
Interestingly, the main differences between our model and 
the SK1 structure were in Arg185 and Arg191, which were 
excluded from the model because the sequence identity in 
that region was below the required threshold for homology 
modeling (< 30%). These residues contribute to binding 
of the β-phosphate of ADP in the crystal structure and 
were confirmed to contribute to ATP binding as alanine 
mutations of Arg185 and Arg191 substantially reduced 
SK1 activity (Figure 1B).
Virtual screening identifies MP-A08 as a novel 
SK-selective inhibitor
The validated model of the ATP-binding pocket 
of SK1 was then used in a virtual screen to identify 
novel inhibitors of SK1. Libraries composed of 120,000 
compounds were docked into the ATP-binding pockets 
of the SK1 model and DgkB structure using a two-
step screening approach. Candidate compounds were 
chosen that displayed preferential docking scores and 
orientation for the ATP-binding pocket of SK1 over 
that of DgkB. Physical screening of the top candidate 
compounds was then performed to examine their 
ability to inhibit the activity of purified recombinant 
SK1 in vitro. From this screening we identified several 
novel hit molecules (data not shown) however due 
to superior inhibition and solubility 4-methyl-N-[2-[[2-
[(4-methylphenyl)sulfonylamino]phenyl]iminomethyl]
phenyl]benzenesulfonamide (henceforth referred to as 
MP-A08) (Figure 1C) was chosen for further investigation 
as an inhibitor of SK1. The molecule contains two 
benzenesulfonamide groups joined by a central benzy-
lideneaniline group.
MP-A08 docked into the ATP-binding pocket of 
SK1 in close association with conserved Motifs 1–3, and 
was predicted to form close associations with Asn22, 
Arg24, Thr54, Ser79, Gly80, Asp81, Gly82, Leu83 
and Ser112 (Figure 1D). To confirm this orientation of 
MP- A08 binding we next assessed its ability to inhibit 
the ATP-binding pocket mutants of SK1 (Figure 1E). 
MP-A08 inhibition of SK1 was reduced by around three-
fold by the T54A, L83A, R185A and S112A mutations 
and approximately two-fold by the S79A, R24A and 
R191A mutations. Interestingly, the R24A mutation did 
not affect SK1 activity (Figure 1B) but reduced MP-A08 
inhibition (Figure 1E), which was in agreement with the 
docking where the Arg24 side-chain was overarching 
the central phenyl rings of MP-A08 (Figure 1D). These 
findings confirm that MP-A08 is an inhibitor targeting the 
ATP-binding pocket of SK1. Together with the docking 
it also suggests that a subset of the residues that bind 
the adenosine component of ATP, namely Arg24, Thr54, 
Glu55 and Leu83, accommodate the amine group from the 
benzene-sulfonamide and the central imine in MP-A08. 
Additionally, the polar side-chains of Ser79 and Ser112 
and the positively charged Arg185 and Arg191 which 
coordinate the negatively charged phosphates of ATP, 
accommodate the bulky phenyl rings and sulfonyl group in 
MP-A08. A lack of activity precluded us from testing the 
affect of mutation at Asp81 on MP-A08 binding; however, 
it is predicted that the acidic side-chain of this residue 
would also contribute to MP-A08 binding.
To assess its selectivity, MP-A08 was tested 
against purified recombinant human SK1 and SK2, with 
both enzymes being similarly inhibited (Figure 1F). 
Notably, unlike some other recently developed SK 
inhibitors [26], comparable inhibition of murine SK1 and 
SK2 was also observed (Figure 1F). We also examined the 
inhibitory activity of MP-A08 against the related human 
lipid kinases, diacylglycerol kinase (DAGK) and ceramide 
kinase (CERK), which both show considerable polypeptide 
sequence similarity to the SKs in most of the conserved 
regions involved in forming the ATP-binding pocket [31] 
(Motifs 1–5). Notably, MP-A08 showed no inhibition of 
human DAGK, and only weakly inhibited CERK when 
employed at 192 μM (Figure 1F). Since SKI-II was 
recently shown to inhibit dihydroceramide desaturase 
[22] we also tested whether MP-A08 had any effects on 
this enzyme. While, consistent with this previous study, 
dihydroceramide desaturase activity was substantially 
blocked by 10 μM SKI-II, no effects were observed by 20 
μM MP-A08 (data not shown). To further assess specificity, 
we next tested MP-A08 against a panel of 140 human 
protein kinases. Consistent with the structural divergence 
of the ATP-binding pocket of SK1 from that of the protein 
kinases, initial screening showed very few protein kinases 
were affected by 25 μM MP- A08, and those that were only 
displayed modest inhibition (Supplementary Table 1). 
Further analysis using very high concentrations of MP-
A08 (250 μM) against seven protein kinases that were 
inhibited by more than 30% in the initial screen, failed 
to show a dose-dependent trend for six of the enzymes. 
Only testis-specific serine kinase 1 (TSSK1) was modestly 
inhibited (by 57%) at this very high concentration of MP-
A08 (Supplementary Table 1).
Inhibition kinetics confirmed that MP-A08 was 
an ATP-competitive inhibitor of human SK1 and SK2 
(Figure 2A–2B). Somewhat surprisingly, MP-A08 was a 
higher affinity inhibitor of SK2 than SK1, with Ki values 
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Figure 2: MP-A08 is a novel ATP-competitive inhibitor for SK1 and SK2. Lineweaver–Burke plots showing inhibition kinetics 
MP-A08 against recombinant SK1 (A) and SK2 (B) with varying ATP concentration. Data show MP-A08 employed at 50 μM (▲) or 25 
μM (■), or with vehicle control (●), and are mean ± SD from four independent experiments. (C) The ATP-binding pocket of the recently 
solved SK1 crystal structure (3VZD) with MP-A08 docked. Each of the regions highly conserved in all SKs (see Supplementary Figure 
1) that comprise the ATP-binding pocket are colored in the same scheme as in Figure 1A. SK1Arg185 and SK1Arg191 are colored in light 
pink. The atoms in MP-A08 are colored according to chemical elements; oxygen in red, nitrogen in blue, and sulphur in yellow. (D) The 
predicted SK2 model is represented with MP-A08 docked. Each of the conserved motifs that comprise the ATP-binding pocket are colored 
as in C. SK2Arg315 and SK2Arg321 are colored in light pink. (E) Assessment of residual SK2 activity in the ATP-binding pocket mutants of 
residues predicted to be important for SK2 binding to MP-A08. SK2 activities were determined after overexpression in HEK293T cells, 
and represented as % activity compared to wildtype SK2 (WT). Empty vector (EV) transfected cells show negligible contribution from 
endogenous SK to the activities displayed. The lower panel shows similar expression levels of all SK2 variants, but all activities were 
adjusted for slight variations in expression. All data shown are mean ± SD (n = 4). (F) Effect of MP-A08 (250 μM) on the activity of SK2 
variants harboring mutations in the ATP-binding site. Values are represented as % activity compared to vehicle control, mean ± SD (n = 4). 
Significance from SK2WT was determined by student t-test (*p < 0.05, **p < 0.01 and ***p < 0.001)
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of 6.9 ± 0.8 μM and 27 ± 3 μM, respectively. In order 
to analyze these differences in binding to SK1 and SK2 
we produced a homology model of SK2 using the recent 
SK1 crystal structure, and then docked MP-A08 into 
the SK1 crystal structure (Figure 2C) and the predicted 
SK2 ATP-binding pocket (Figure 2D). Comparison of 
the SK1 crystal structure and the SK2 model revealed a 
highly conserved ATP pocket with the exception of the 
substitutions at SK2Phe154/SK1Arg24 and SK2Asn187/SK1Arg57 
(Figure 2C–2D, Supplementary Figure 3A–3B). In the 
SK1 structure Arg24 and Thr54 appear to coordinate one 
of the central phenyl rings of MP-A08 and shield the amine 
groups from the basic side-chains of Arg24 and Arg57. The 
second central phenyl ring likely shields the internal amine 
group from the Arg185 and Arg191 side-chains, pointing 
the sulfonyl groups towards Asn22, Ser79 and Leu83 
in SK1 (Figure 2C). One methyl substituted ring points 
out towards the outside of the pocket and the other is 
orientated towards the internal Ser112 and the Arg185 and 
Arg191 side-chains in SK1. The predicted orientation of 
MP-A08 in the ATP-binding pocket of SK2 is altered due 
to the substituted residues at Phe154 and Asn187 (Arg24 
and Arg57 in SK1, respectively). The bulky aromatic 
side-chain of Phe154 and the smaller basic side-chain of 
Asn187 alter both the size and charge of the ATP pocket 
in SK2 (Figure 2D and Supplementary Figure 3A–3B). 
The terminal methylphenyl rings point towards the side-
chain of Thr184 and Asn152. Compared to the SK1 
pocket, the central phenyl rings of MP-A08 are shifted 
towards the bottom of the SK2 pocket, coordinated by 
Arg315 and Arg321. The sulfonyl groups are tethered via 
hydrogen bonding to Asn152 and Ser242 side-chains.
To validate the SK2 model we tested alanine 
mutants of the SK2 ATP pocket predicted to contribute to 
MP-A08 binding. As was found with the corresponding 
residues in SK1, SK2 activity was significantly reduced 
with alanine mutations at Asn152, Thr184, Ser242, Arg315 
and Arg321 (Figure 2E). Conversely, alanine mutations of 
either Phe154 or Leu213 displayed a two-fold increase in 
SK2 activity (Figure 2E), due to the removal of the bulky 
side-chains. These residues are involved in binding the 
adenosine of ATP, therefore removal of either of these 
side-chains appears to reduce steric hindrance in this 
region of the pocket. We next assessed the SK2 mutants 
for MP-A08 binding. In agreement with the docking 
we found that alanine mutations at Asn152, Thr184 
and Leu213 gave some reduction in SK2 inhibition 
by MP-A08, while mutations at Arg315 and Arg321 
resulted in much less inhibition of SK2 by this inhibitor 
(Figure 2F). Alanine mutation at Phe154 had only a minor 
effect on SK2 inhibition by MP-A08 as it is shielded by 
the side-chain of Asn152 (Figure 2F), which was, again, 
in agreement with the docking. Surprisingly, mutation at 
Ser242 did not affect MP-A08 binding in SK2 despite the 
predicted hydrogen bonding interaction of its side-chain 
hydroxyl. It appears that for SK2 Arg315 and Arg321 
tether MP-A08 in the pocket without the involvement of 
Ser242, whilst in SK1 Arg185, Arg191 and Ser112, all 
contribute to MP-A08 binding in this region of the ATP 
pocket.
MP-A08 does not induce degradation of SK1
Some SK inhibitors, such as SKI-II and PF-543 
have been found to inhibit SK1 in cells by targeting the 
protein for proteasomal degradation [33–36,  45]. Therefore 
we investigated whether MP-A08 induced proteasomal 
degradation of SK1. As reported previously [34], treatment 
with SKI-II caused a reduction in SK1 levels which 
could be restored with the proteasome inhibitor MG132 
(Figure 3). Conversely, however, cell treatment with MP-
A08 had no affect on SK1 protein levels, demonstrating that 
MP-A08 does not induce degradation of SK1 (Figure 3).
MP-A08 inhibits S1P production in cells and 
increases pro-apoptotic sphingolipids
To test whether MP-A08 was a cell permeable 
SK inhibitor we next examined its ability to block S1P 
generation in cells. Treatment of Jurkat cells pre-labeled 
with 3H-sphingosine with 15 μM MP-A08 resulted in 
significantly reduced cellular S1P generation (Figure 4A), 
confirming this compound is cell permeable and able to 
block SK activity in cells. In order to assess the impact 
Figure 3: MP-A08 does not induce degradation of SK1. Western blots showing the effect of SKI-II (10 μM, 24 h) or MP-A08 
(30 μM) treatment in the presence or absence of MG132 (10 μM, 24 h) on SK1-FLAG in HEK293 cells (upper panel). Tubulin was used as 
a loading control (lower panel). Results are representative of 2–3 independent experiments.
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Figure 4: MP-A08 inhibits cellular S1P production, increases levels of sphingosine and ceramides, and alters cell 
signaling pathways associated with apoptosis and proliferation. (A) The effect of MP-A08 on cellular S1P formation was 
determined in Jurkat cells as described in Materials and Methods, and presented as % vehicle control. Values are mean ± SD (n = 4). 
Significance was determined by student t-test (*p < 0.05). (B) Mass spectrometric analysis of sphingolipids from Jurkat cells treated 
with 15 μM MP-A08 (black bars) or vehicle control (grey bars) for 6 h (top) or 16 h (bottom). S1P levels in cell lysates were determined 
by SIP ELISA. Significance compared to vehicle control was determined by student t-test (*p < 0.05, **p < 0.01 and ***p < 0.001) 
(n = 3).
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of MP-A08 on endogenous cellular sphingolipids the 
sphingolipid profile of MP-A08-treated Jurkat cells was 
analyzed (Figure 4B). Significant increases in levels 
of dihydrosphingosine, C16-dihydroceramide and all 
ceramides examined were observed at both 6 and 16 h after 
cell exposure to MP-A08 (Figure 4B). Indeed, cells treated 
with MP-A08 for 6 hours displayed significant increases 
in dihydrosphingosine and all ceramide species compared 
to vehicle-treated cells, but most notably in C18-, C20- 
and C20:1-ceramide, which displayed 3.7, 3.5 and 5.8-
fold increases, respectively (Figure 4B). At 16 h after 
MP-A08 treatment the levels of C18-, C20- and C20:1-
ceramides remained significantly elevated compared to 
vehicle controls (3.4, 2.8, 3.9-fold, respectively), while 
levels of C14- and C18:1-ceramide, dihydrosphingosine 
and sphingosine were elevated further compared to the 6 
hour treatment. As expected, S1P levels were significantly 
decreased at both time points with 2-fold reduction at 6 h 
and a 3.5-fold reduction after 16 h.
MP-A08 induces mitochondrial-mediated 
apoptosis
As MP-A08 treatment was found to increase levels 
of pro-apoptotic ceramides we next assessed the affects of 
MP-A08 on signaling pathways associated with survival 
and proliferation. S1P is known to regulate the Akt and 
MAPK pathways via signaling through the S1P G-protein 
coupled receptors and via other unknown intracellular 
pathways [37]. As expected, MP-A08 treatment caused 
a dose-dependent loss in activation of the pro-survival 
and pro-proliferative Akt and ERK1/2 pathways, and 
induction of the apoptosis-associated p38 and JNK 
pathways (Figure 5A).
Previous studies have demonstrated that knockdown 
or inhibition of SKs induces apoptosis in many cell types 
[11, 38, 39]. Thus, we next assessed the effects of MP-A08 
on induction of apoptosis via an array of apoptosis markers; 
caspase-3 cleavage and activation, PARP cleavage, 
Annexin V staining, and mitochondrial permeability 
transition by TMRE staining (Figure 5B–5F). Treatment 
of Jurkat cells with 10 and 15 μM MP-A08 caused a dose-
dependent induction of caspase 3 activity (Figure 5B). This 
was confirmed by immunoblotting for caspase 3 and PARP 
cleavage products, which demonstrated a dose-dependent 
activation of caspase 3 and inactivation of PARP with 
MP-A08 treatment (Figure 5C). Consistent with this, 
MP- A08 also induced cell surface expression of annexin 
V in a dose-dependent manner (Figure 5D). To verify that 
MP-A08 was inducing mitochondrial-mediated apoptosis, 
Jurkat cells overexpressing the anti-apoptotic Bcl2 protein 
were treated with MP-A08 and assessed for apoptosis. 
Bcl2 overexpression blocked both MP-A08-induced 
annexin V staining and PARP cleavage compared to the 
parental cells (Figure 5D–5E). MP-A08 treatment of cells 
also reduced TMRE staining in a dose-dependent manner, 
indicating mitochondrial membrane permeabilization 
consistent with induction of mitochondrial-mediated 
apoptosis (Figure 5F).
To validate the SKs as the targets of MP-A08-
induced apoptosis we next assessed the sensitivity 
of primary SK1/SK2 double knockout (dKO) mouse 
embryonic fibroblasts (MEFs) to MP-A08 treatment 
(Figure 5G). Unlike wildtype MEFs, which showed 
a dose-dependent increase in apoptosis with MP-A08 
treatment, dKO MEFs had an elevated basal level of 
apoptosis that was unaffected by MP-A08 treatment 
(Figure 5G). These results strongly suggest that MP-A08 
induced-apoptosis is mediated by inhibition of the SKs.
MP-A08 blocks survival and neoplastic growth 
of a range of cancer cell lines
Due to the ability of MP-A08 to induce apoptosis 
in Jurkat cells we then tested its affects on the growth of 
a range of solid cancer cell lines, including three from 
the NCI60 human tumor cell line panel (A549 lung 
adenocarcinoma cells, and MCF-7 and MDA-MB-231 
breast adenocarcinoma cells) (Figure 6A), as well as BJ7 
human foreskin fibroblasts transformed via the expression 
of V12-Ras, the telomerase catalytic subunit and the 
SV40 large and small T antigens [40] and the parental 
untransformed foreskin fibroblast line, BJ1 (Figure 6B). 
These cell lines, along with Jurkat cells, were treated 
with varying doses of MP-A08 to determine the median 
effective concentration (EC50) to block cell proliferation 
(Figure 6A–6B, 6D). Growth of all five of the transformed 
cell lines (A549, MCF-7, MDA-MB-231, Jurkat and BJ7) 
was blocked by MP-A08, but with varying sensitivities 
(Figure 6A–6B, 6D), while notably the growth of the 
untransformed BJ1 fibroblast line was not affected by 
MP-A08 (Figure 6B). We next assessed the EC50 of MP-
A08 required to block neoplastic, anchorage-independent 
growth of the solid tumor cell lines in in vitro colony 
formation assays, as a better indicator of anti-neoplastic 
activity. Again, MP-A08 blocked neoplastic growth of all 
four cell lines (Figure 6C–6D). Interestingly, however, 
the cell lines displayed very different sensitivities in 
the colony formation and cell growth assays. A549 
cells, for example, were least sensitive to MP-A08 in 
cell proliferation assays, but most sensitive in colony 
formation assays (Figure 6C–6D).
MP-A08 suppresses the growth of human lung 
tumor xenografts in mice
Prior to examining the anti-neoplastic effects of 
MP-A08 in vivo, we first sought to establish the maximal 
tolerated dose of MP-A08 in NOD/SCID mice. No 
adverse side effects were observed following daily i.p. 
administration of 50, 75 or 100 mg/kg MP-A08 to mice for 
14 days through measurement of body weight, white cells, 
Oncotarget7073www.impactjournals.com/oncotarget
Figure 5: MP-A08 induces apoptosis in a sphingosine kinase-dependent manner. (A) MP-A08 alters survival and proliferative 
signaling. Jurkat cells were treated with varying doses of MP-A08 (10–20 μM) for 6 h. Lysates were resolved by SDS-PAGE and analyzed 
by immunoblotting with antibodies against p-AKT(Ser473), p-ERK1/2, p-p38, and p-JNK (Cell Signaling). Actin was used as a loading 
control. Results are representative of two independent experiments. (B) Jurkat cells were treated with vehicle, 10 or 15 μM MP-A08 for 
5 h and then assessed for caspase 3 activity (mean ± SD, n = 3; *p < 0.05 by Student’s t-test). (C) Jurkat cells were treated with vehicle or 
MP-A08 (5–20 μM) for 6 h. Lysates were resolved by SDS-PAGE and analyzed for caspase 3 and PARP cleavage by immunoblotting with 
antibodies against caspase 3 and PARP, with tubulin used as a loading control. Results are representative of two independent experiments. 
(D) Jurkat (black bars) or Bcl2-expressing Jurkat cells (grey bars) were treated with MP-A08 (5–15 μM) or vehicle control for 24 h, and then 
stained with Annexin V to assess apoptosis. Values are represented as % of no treatment control (mean ± SD, n = 3; *p < 0.05 by Student’s 
t-test). (E) Lysates from Jurkat or Bcl2-expressing Jurkat (Bcl2-Jurkat) cells treated with MP-A08 (5–15 μM) or vehicle control for 16 h were 
assessed for PARP cleavage by immunoblotting with PARP antibodies, with tubulin used as the loading control. Results are representative 
of two independent experiments. (F) Jurkat cells were treated with 10 or 15 μM MP-A08 or vehicle control for 5 h and stained with TMRE 
to test for changes in mitochondrial permeability (mean ± SD, n = 3; *p < 0.05 by Student’s t-test). (G) Mouse embryonic fibroblasts from 
wildtype (●) or SK1/SK2 double knockout mice (■) were treated with MP-A08 or vehicle control overnight. Cells were stained with DAPI 
and assessed for apoptosis by visualizing nuclear condensation using confocal microscopy. Values are mean ± SD (n = 3).
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blood hemoglobin, or platelet numbers (Supplementary 
Figure 4). Furthermore, no differences were detected in 
tissue pathology of the kidney, liver, heart and spleen 
between these MP-A08 treated mice and vehicle treated 
mice, suggesting low toxicity of MP-A08.
We next examined in vivo efficacy of MP-A08 to 
attenuate growth of A549 human lung adenocarcinoma 
xenografts in mice. Subcutaneous xenografts of A549 
cells were established in NOD/SCID mice and grown 
to a volume of approximately 75 mm3 before mice were 
treated with MP-A08 at 100 mg/kg, six times a week for 
two weeks. MP-A08 significantly reduced tumor volume 
and weight (Figure 7A–7B). Consistent with in vivo SK 
inhibition, excised tumors from MP-A08 treated mice 
displayed significantly lower S1P compared to the tumors 
from vehicle control mice (Figure 7C). MP-A08 treated 
tumors exhibited significantly higher levels of apoptotic 
cell death compared to the vehicle control as indicated by 
TUNEL staining (Figure 7D). In addition to promoting 
cell growth and survival, SK has an established role 
in promoting cancer angiogenesis [41]. As expected, 
MP- A08 treated tumors showed reduced vasculature as 
signified by a reduction in CD31 positive blood vessels 
(Figure 7E). This data, therefore, suggests MP-A08 acts 
as an anti-cancer agent by both inducing apoptosis and 
blocking angiogenesis.
DISCUSSION
In this study we have identified MP-A08 as a novel, 
first-in-class selective ATP-competitive inhibitor of SK1 
and SK2. MP-A08 alters the balance of the sphingolipid 
rheostat away from anti-apoptotic, pro-proliferative S1P, 
Figure 6: MP-A08 inhibits neoplastic growth of human cancer cells in vitro. (A) For growth assays, values were determined 
for adherent cells lines by MTS assay and by flow cytometry for Jurkat cells (suspension) with varying concentrations (1.56–125 μM) of 
MP-A08 (48 h treatment). A549 (■), MCF7 (□), MDA-MB-231 (○), Jurkat (▼). Values are displayed as % vehicle control, mean ± SD 
(n = 3–4). (B) Growth of parental BJ1 (□) and transformed BJ7 (■) fibroblasts were determined by MTS assay with varying concentrations 
(1.25–50 μM) of MP-A08 (48 h treatment). Values are displayed as % vehicle control, mean ± SD (n = 3–4). (C) For colony formation 
assays, adherent cells lines A549 (■), BJ7 (▲),MCF7 (□), and MDA-MB-231 (○) were plated in 0.33% (final) low-melting point agarose 
with MP-A08 at varying concentrations (10–50 μM). This was overlaid onto 0.5% DMEM-low-melting agarose gel. Colonies were 
assessed by light microscopy and quantified using ImageJ after 14–21 days. Values are displayed as % vehicle control, mean ± SD (n = 3–4). 
(D) Curve-fitting for EC50 values for A–D were determined using non-linear regression analysis GraphPad (Prism) (n = 3–4, R2 > 0.95).
Oncotarget7075www.impactjournals.com/oncotarget
Figure 7: MP-A08 reduces tumor burden in an A549 xenograft mouse model. (A) Mice bearing A549 xenografts were treated 
i.p. with 100 mg/kg MP-A08 or vehicle control at the times indicated (arrows). Mean tumor volumes ± SEM are shown (n = 8 per group). 
Statistical analysis on all data points was performed by two-way ANOVA. (B) After two weeks of treatment with MP-A08 (100 mg/kg) 
or vehicle control, tumors were excised and weighed (n = 8 per group, *p < 0.05 by Student’s t-test). (C) S1P/dhS1P levels in the tumor 
homogenates were determined by S1P ELISA. Values are represented as mean +SD (n = 4–5), *p < 0.05 by Student’s t-test) (D) MP-A08 
induces apoptosis in xenograft tumors. Representative TUNEL-stained xenograft sections from MP-A08 or PEG treated mice as presented 
in (A–B). A representative 40× image is shown. The scale bar indicates 100 μM. Image intensity was quantified using ImageJ (right)  
(n = 8 per group, *p < 0.05 by Student’s t-test). (E) MP-A08 reduces tumor angiogenesis. Representative CD31-stained tumor sections from 
MP-A08 or vehicle control-treated mice as presented in (A–B). CD31 positive vessels per field of view were quantitated (n = 8 per group; 
*p < 0.05 by Student’s t-test). The scale bar indicates 50 μM.
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towards pro-apoptotic sphingosine and ceramide, and as 
a result blocks neoplastic growth and induces apoptosis 
in a range of human cancer cell lines. Furthermore, 
MP-A08 is active in vivo, inhibiting the growth of human 
lung adenocarcinoma xenograft tumors in mice via a 
mechanism that involved both induction of tumor cell 
apoptosis and reduction in tumor angiogenesis.
Previously developed SK inhibitors have almost 
exclusively targeted the sphingosine-binding pocket 
of these enzymes. As these inhibitors often retain 
sphingosine-like characteristics, just like sphingosine, 
they can have off-target affects [11, 20, 22–24]. The 
sphingosine-analog inhibitor SKI-II, for example, 
inhibits dihydroceramide desaturase, an enzyme in the 
de novo sphingolipid synthesis pathway [22]. Similarly, 
the sphingosine-like FTY720, which shares a common 
backbone with other sphingosine-analog inhibitors, can 
at high concentrations disrupt membranes, inhibit other 
sphingosine-binding or lipid metabolizing enzymes such 
as ceramide synthase and S1P lyase, and also target 
protein phosphatase 2A, the pro-survival 14–3-3 protein, 
and autotaxin [42]. For this reason we sought ways to 
target the ATP pocket of SK1 for inhibitor development; a 
strategy employed with success with many protein kinase 
inhibitors despite these proteins possessing a very high 
degree of structural conservation in their ATP binding 
sites [43, 44]. For the SKs, this approach was particularly 
attractive as their ATP-binding pockets are structurally 
distinct from protein kinases, as well as almost all 
other lipid kinases [28, 32], allowing it to be effectively 
exploited for inhibitor development.
Until very recently no structural information was 
available for the SKs. Therefore, we employed a homology 
modeling and in silico docking approach to screen for 
inhibitors targeting the ATP-binding pocket of SK1. 
Notably, retrospective comparison showed our predicted 
SK1 model aligned very closely with the recently 
published SK1 crystal structure [32]. Using modeling 
and mutagenesis we have built on the mechanistic 
understanding of catalysis by the SKs obtained from 
the SK1 crystal structure by characterizing the residues 
required for ATP binding and catalysis of SK1. Of note, 
our analysis demonstrated the requirement of residues 
from all five regions highly conserved in the SKs; 
21LNPRGG26, 54TERR57, 79SGDGLMHE86, 111GSGN114 
and 340VDGE343 (where underlined residues denote where 
mutation reduced or abolished SK1 activity). Furthermore, 
our prediction and mutagenesis of the ATP-binding pocket 
of SK2 confirmed its high overall conservation with that 
of SK1, but also uncovered key differences in this region 
between the two human SK isoforms that may allow for 
the development of isoform-selective ATP-competitive 
inhibitors of these enzymes.
Identification and subsequent analysis of MP-
A08 inhibition revealed it to act, as expected, as an ATP 
directed inhibitor of SK1. MP-A08 also inhibited SK2 
in a comparable manner, although surprisingly with a 
somewhat higher affinity than SK1. Analysis of MP-A08 
docking into the SK1 structure and SK2 model suggests 
that the Phe154 and Asn187 substitutions in the ATP-
binding pocket of SK2 (compared to Arg24 and Arg57 
in SK1, respectively) may explain, in part, the increased 
MP- A08 affinity for SK2. These amino acid substitutions 
in the SK2 pocket are predicted to cause an altered 
arrangement of the phenyl rings of MP-A08, binding 
the molecule deeper into the pocket. Interestingly, 
inhibition of SK1 by MP-A08 did not induce proteasomal 
degradation. This is in contrast to the sphingosine-analog 
inhibitors SKI-II [34], PF-543 and 55–21 [45]. Therefore it 
is tempting to speculate that inhibitor-induced degradation 
is a property regulated by binding to the sphingosine 
pocket and not the ATP pocket of SK1.
Consistent with the divergent structure of the ATP-
binding pocket of SK1 from protein kinases, MP-A08 
displayed a high degree of specificity for the SKs. This 
is in stark contrast to CB5468139, the only other ATP-
binding site directed SK1 inhibitor described to date, 
which inhibited a broad array of protein kinases [46]. 
Indeed, TSSK1 appeared the only potential off-target 
of MP-A08 in our kinome screen, although the in vitro 
inhibition of this protein kinase by MP-A08 was only 
modest, even when the inhibitor was employed at 250 
μM. Notably, TSSK1 expression is restricted to the testis, 
and thus any potential inhibitory effect on this protein 
kinase is unlikely to impact on the findings of this study. 
Furthermore, due to its role in spermatid maturation, 
TSSK1 has been targeted for contraceptive development 
[47], meaning any off-target inhibition of this enzyme is 
unlikely to present serious detrimental side-effects in vivo. 
Interestingly, our studies also showed that Ser79, Leu83 
and Ser112 of SK1 contribute to MP-A08 binding. Since 
these residues are not conserved in CERK and DAGK, 
this is consistent with these residues conferring selectivity 
of MP-A08 for the SKs over other related members of the 
SK/DAGK superfamily.
It is notable that MP-A08 significantly increased 
the cellular levels of sphingosine, dihydrosphingosine 
and all ceramide and dihydroceramide species examined 
(Figure 4B). Unlike SKI-II which displays off-target 
inhibition of dihydroceramide desaturase, increases in 
dihydroceramides with MP-A08 treatment are likely 
induced by ceramide accumulation and re-equilibration 
of all upstream pre-cursors (including dihydroceramides 
and dihydrosphingosine). Our findings with MP-A08 
are consistent with almost all previous studies that have 
found significant increases in ceramide levels following 
genetic ablation, or transient knockdown or inhibition of 
SK1, with this correlating with induction of apoptosis [38, 
39, 48, 49]. This is, however, in stark contrast to some 
recently reported high affinity SK inhibitors that fail to 
induce apoptosis or show anti-neoplastic effects [25–27]. 
Notably, where examined, these high affinity inhibitors 
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did not show any enhanced ceramide levels when used 
at concentrations sufficient to inhibit SK1 [25, 27]. This, 
combined with observed increases in sphingosine levels by 
these inhibitors, which would normally be associated with 
enhanced ceramides [21, 38, 39, 46, 50, 51], suggest these 
high affinity inhibitors may exhibit inhibitory effects on at 
least some ceramide synthases [45], potentially explaining 
their impotence as anti-neoplastic agents.
Examination of the downstream signaling affects of 
SK1/2 inhibition by MP-A08 revealed a dose-dependent 
reduction in phospho-Akt and phospho-ERK1/2 
(Figure 5A), indicating a dampening of the phos-
phoinositide 3-kinase/Akt and Ras/ERK1/2 pathways, 
respectively. MP-A08 concomitantly induced a dose-
dependent activation of stress pathways through 
phospho-p38 and phospho-JNK (Figure 5A). This loss of 
pro-survival and pro-proliferative signaling and induction 
of stress-induced signaling, combined with induction 
of numerous markers of apoptosis, is completely in 
agreement with known effects of blockade of the SK 
pathway [21, 38, 39, 46, 50, 51]. Furthermore, the absence 
of effects of MP-A08 on MEFs lacking SK1 and SK2 
provides considerable evidence that the observed cellular 
effects of this molecule are mediated via SK1/2 inhibition. 
Interestingly, transient SK inhibition in wildtype MEFs 
resulted in greater apoptosis than that observed with 
genetic ablation of the SKs in the dKO MEFs. While the 
reasons for this remains unclear, it is possible that the 
chronic loss of SKs in the dKO cells results in selection 
of a population of MEFs that is somewhat more resistant 
to apoptosis.
Examination of the sensitivities to MP-A08 
of different cancer lines showed both reduced cell 
proliferation and in vitro neoplastic growth, with EC50 
values comparable to those of a number of other widely 
employed SK inhibitors [46, 52]. In addition, MP-A08 
did not affect the growth of the parental untransformed 
BJ1 fibroblast cell line, while the transformed BJ7 cells 
displayed a dose-dependent reduction in cell growth with 
treatment (Figure 6B). This suggests that transformed cells 
are more sensitive to MP-A08 consistent with previous 
non-oncogene addiction theories for the SKs [53, 54].
With A549 human lung adenocarcinoma cells 
demonstrating sensitivity to MP-A08 we undertook a 
mouse xenograft study with these cells, with MP-A08 
significantly reducing tumor growth, demonstrating 
clear efficacy of this inhibitor in vivo. Indeed, MP-
A08 enhanced tumor apoptosis, and consistent with the 
known role of SK1-derived S1P as a potent angiogenic 
factor through S1P1 receptor [55–57], also reduced tumor 
vascularization (Figure 7D).
In conclusion, here we report a first-in-class ATP-
binding site-directed small molecule SK inhibitor, MP-
A08 that was discovered using a combined approach 
of structural homology modeling of the ATP-binding 
site of SK1 and in silico docking with small molecule 
libraries. MP-A08 is a highly selective ATP-competitive 
inhibitor that inhibits both SK1 and SK2. MP-A08 blocks 
pro-proliferative signaling, induces apoptosis in an 
SK-dependent manner and represses the growth of human 
lung adenocarcinoma in a mouse xenograft model by both 
inducing tumor apoptosis and inhibiting angiogenesis. 
Therefore, this newly developed SK inhibitor that targets 
the ATP-binding pocket provides a promising candidate 
for further development as a potential cancer therapy.
MATERIALS AND METHODS
Prediction of SK structures by homology 
modeling
A multiple sequence alignment of human DAGKα 
(Genbank Accession number: NP_963848), human 
DAGKζ (NP_963290), human CERK (NP_073603), 
Escherichia coli YEGs (P76407), Staphylococcus aureus 
DgkB (Sequence from PDB code: 2QV7) and human 
SK1a (Q9NYA1) was performed using ClustalW [58]. 
This alignment was used as input for Modeller 9v6 [59]. 
DgkB (2QV7) and YegS (2JGR) crystal structures were 
used as templates for homology modeling. Due to poor 
homology with the template structures, residues 1–12, 
162–189 and 203–230 of human SK1 were excluded from 
the SK1 model. The model was optimized using 50 cycles 
of Refmac structure idealization [60]. The CCP4 software 
suite was used for model assessment and structural 
alignments using Procheck and Superpose modules, 
respectively [60]. Figures were produced using the Pymol 
graphics program [61]. The structural model of human 
SK2 was produced as described above using the human 
SK1 crystal structure [32] bound with ADP (3VZD) as 
a template. Due to large insertions in the SK2 sequence 
(AAH10671) residues 1–142, 355–370 and 609–618 were 
excluded from the SK2 model.
In silico molecular screening
The SK1 structural model and DgkB crystal 
structure were prepared for docking using the DockPrep 
module in Chimera [62]. Docking was performed using 
DOCK6 [63, 64] on the eResearch SA Hydra server. 
Docking parameters were optimized using comparisons 
of the structure of DgkB co-crystallized with ADP and 
with the DgkB structure docked with ADP. For in silico 
screening, a virtual library of 120,000 compounds was 
generated from databases (Sigma-Aldrich, Calbiochem, 
and the National Cancer Institute Chemical and Natural 
Products libraries) [65]. The docking was carried out in 
two stages: initial low stringency screening, and then high 
stringency screening. Default high stringency docking 
parameters were used with a minimum anchor size 
of two atoms and scored with chemical matching. All 
compounds that docked at high stringency were assessed 
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by score, rank and visual assessment. Candidates were 
chosen for biological testing and were sourced from the 
Drug Synthesis and Chemistry Branch, Developmental 
Therapeutics Program, Division of Cancer Treatment and 
Diagnosis, National Cancer Institute, USA.
Chemical synthesis
MP-A08 was synthesized, purified and identity 
verified by ChemBridge Inc (San Diego, USA) with > 
95% purity.
Construction of SK mutants
FLAG-tagged human SK1 and SK2 constructs 
in pcDNA3 vector (Invitrogen) have been previously 
described [66, 67]. Quikchange® PCR mutagenesis 
was carried out with forward and reverse mutagenic 
oligonucleotides (Supplementary Table 2). DNA sequencing 
verified the integrity of all mutated cDNAs.
Cell culture
HEK293 (human embryonic kidney, 293c18 cells, 
ATCC# CRL-10852 ), A549 (human lung adenocarcinoma, 
ECACC# 86012804), untransformed parental (BJ1) and 
transformed human foreskin fibroblasts (BJ7) [40], MCF7 
(human mammary adenocarcinoma, ECACC# 86012803) 
and MDA-MB-231 (human mammary adenocarcinoma, 
ATCC# HTB-26) cells were cultured in Dulbecco’s 
modified Eagle’s medium (Gibco, Invitrogen), containing 
10% fetal bovine serum (Bovagen), 2 mM glutamine, 
0.2% (w/v) sodium bicarbonate, 1 mM HEPES, penicillin 
(1.2 mg/ml) and streptomycin (1.6 mg/ml). Jurkat (human 
T cell lymphoblast) and Jurkat-Bcl2 cells were cultured in 
suspension in RPMI medium containing 10% fetal bovine 
serum (Bovagen), 2 mM glutamine, 0.2% (w/v) sodium 
bicarbonate, 1 mM HEPES, penicillin (1.2 mg/ml) and 
streptomycin (1.6 mg/ml). All cells were grown at 37°C, 
5% CO2 in a humidified incubator.
SK1/SK2 double knockout MEFs were generated 
from timed matings of female SK1+/−/SK2−/− mice with male 
SK1−/−/SK2+/− mice. Fibroblasts from 11.5 day post coitum 
embryos were isolated and cultured in DMEM containing 
10% bovine calf serum (Bovogen), penicillin (1.2 mg/
ml) and streptomycin (1.6 mg/ml) at 37ºC in a humidified 
atmosphere with 10% CO2. Cells were genotyped to 
identify cultures with SK1/SK2 double knockout genotype. 
Wild-type MEFs were generated from 14.5 day post coitum 
embryos and cultured as described above.
Assaying SK ATP-binding pocket mutants for 
activity
HEK293 cells were seeded in 6-well plates and 
were transiently transfected using LipofectamineTM 
2000 Transfection Reagent (Invitrogen) according to the 
manufacturer’s protocol. Cells were harvested 24 h post-
transfection, and cell pellets were resuspended in 50 mM 
Tris-HCl buffer (pH 7.4) containing 150 mM NaCl, 10% 
glycerol, 1 mM EDTA, 0.05% Triton X-100 (excluded 
for SK2 samples), 2 mM Na
3
VO4, 10 mM NaF, 10 mM 
β-glycerophosphate, 1 mM dithiothreitol and protease 
inhibitor cocktail (Roche). Cells were lysed by sonication 
and diluted in extraction buffer for assays (1:1000 final 
dilution). Expression levels of FLAG-tagged SK1/2 
proteins were assessed by SDS-PAGE and anti-FLAG 
immunoblotting. SK1 and SK2 activity was determined 
using d-erythro-sphingosine and [γ32P] ATP as substrates, 
as described previously [68].
Generation of recombinant proteins in insect 
cells
Baculovirus SK1 expression constructs encoding for 
human SK1a with a c-terminal TEV-cleavable 6xHis tag 






pcDNA3-SK1 [66] as a template. The resultant product 
was cloned into pFastBac1 (Invitrogen) by digestion with 
EcoRI. Recombinant human SK1 protein was expressed 
using the baculovirus expression system in Sf9 cells and 
purified as previously described [28].
Purified recombinant human SK2 protein with 6xHis 
and 3xhemagglutinin (HA) tags was generated in Sf9 cells 
and purified as detailed previously [67].
Human ceramide kinase cDNA (Genbank 
Accession number NM_022766) was amplified from 
human placenta cDNA with primers: 5ʹ-TAGGATCCG 




cloned into pFastBac1 following digestion with BamHI 
and EcoRI. Human DAGK cDNA (DAGKα; NM_201444) 







ATTG-3ʹ. The PCR product was digested with HindIII and 
cloned into pFastBac1. Sequencing verified the orientation 
and integrity of all the cloned cDNAs. Recombinant 
bacmids and baculoviruses were produced according to 
the manufacturers’ protocols. To generate CERK and 
DAGKα proteins Sf9 cells (2 × 109 cells) were infected 
with the recombinant baculovirus (MOI 5–10) for 96 h. 
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Infected cells were harvested and snap frozen and stored 
at –80°C until required. Cell pellets were resuspended in 
Buffer A (50 mM Tris-HCl buffer pH 7.6, 150 mM NaCl, 
10% glycerol (w/v), 40 mM imidazole, and protease 
inhibitors (EDTA-free Complete™, Roche). Triton X-100 
was added to a final concentration of 1% (v/v) and the cell 
suspension incubated on ice for 30 min. The lysate was 
clarified by centrifugation at 50,000 × g for 20 minutes at 
4°C. The resulting lysate was incubated with 1.5 ml Buffer 
A-equilibrated Nickel-NTA sepharose (GE Healthcare) 
and incubated at 4°C for 30 minutes with shaking. The 
Nickel-NTA was packed into a column and washed with 
5 column volumes of Buffer A. The protein was eluted 
with Buffer A containing 0.2 M imidazole.
MP-A08 cross-screening
SK1 and SK2 activity was determined using 
d-erythro-sphingosine (solubilized in fatty acid-free 
bovine serum albumin) and [γ32P] ATP as substrates, as 
described previously [68]. DAGK assays were performed 
using β-octylglucoside solubilized dioleoyl-s,n-glycerol 
(DAG) and phosphatidylserine (PS), based on methods 
previously described [69]. CERK assays were performed 
as described previously [70]. Cross-screening assays 
were carried out using 20 μM ATP (0.5 μCi [γ32P]ATP) 
and contained either MP-A08 (0.1 mg/ml, 192 μM) or 
vehicle control (1% DMSO/9% (v/v) ethanol final). 
Data are represented as % activity compared to vehicle 
control. For determination of kinetic constants SK assays 
were carried out as described above with 7.8–500 μM 
ATP and 100 μM sphingosine and treated with either 
vehicle (0.25% DMSO/2.25% (v/v) ethanol), 25 or 50 μM 
MP-A08. Kinetic constants were calculated using non-
linear regression in Graphpad Prism 5.
Screening of MP-A08 for inhibitory activity against 
a panel of 140 protein kinases encompassing the major 
enzymes within this protein family was performed at 
the Dundee International Centre for Kinase Profiling. 
Dihydroceramide desaturase assays were carried out in 
intact Jurkat cells as described previously [71].
SK1 degradation assays
Flp-In T-Rex HEK293 cells (Invitrogen) with 
doxycycline-inducible expression of FLAG-tagged human 
SK1 were generated as previously described [34, 72]. 
Expression of wild-type SK1 in Flp-In T-Rex HEK293 
cells was induced with low concentrations of doxycycline 
hyclate (50–200 ng/ml) that resulted in approximately 
10-fold increases in SK1 activity above basal levels. After 
24 h, cells were treated with 10 μM SKI-II or 30 μM 
MP-A08 with or without 10 μM MG132. PEG400 0.35% 
(v/v), 0.58% (v/v) DMSO was used as the vehicle control. 
Cells were harvested after 24 h treatment and assessed 
for SK1 levels by SDS-PAGE and immunoblotting using 
anti-FLAG (Sigma) or anti-Tubulin (Abcam) antibodies, 
as described previously [34].
Sphingolipid analysis
S1P generation in cells was assessed in Jurkat 
cells suspended at 5 × 105 cells in 1 ml RPMI containing 
0.5% FBS. Cells were treated with 15 μM MP-A08 or 
vehicle control (0.06% (v/v) DMSO/0.54% (v/v) ethanol) 
for 4.5 h at 37°C and 5% CO2. Cells were labeled with 
0.5 μCi 3H-sphingosine (Perkin Elmer), incubated for 
30 min at 37°C and 5% CO2, and then harvested by 
centrifugation at 1500 × g for 1 min, washed once with 
cold phosphate-buffered saline. Cells were lysed in 300 μl 
of acidified methanol (methanol:HCl, 100:1, by vol.), 
and S1P (including 3H-S1P) extracted by the addition of 
300 μl of chloroform, 300 μl of 2M KCl and 30 μl of 3M 
NaOH. The samples were mixed and then centrifuged at 
13000 × g for 5 min to separate the chloroform and 
aqueous/methanol phases, which under these alkaline 
conditions contained the partitioned 3H-sphingosine 
and 3H-S1P, respectively. 3H-S1P in the upper aqueous/
methanol phase was then determined by scintillation 
counting.
Sphingolipid mass spectrometric analyses analysis 
was performed on 5 × 106 Jurkat cells treated in the 
same manner as above for 6 h or 16 h with either 15 
μM MP-A08 or vehicle control. For mass spectrometric 
analyses cells were pelleted, lyophilized and sphingosine, 
ceramides and their dihydro species assessed at the 
Medical University of South Carolina Lipidomics Core 
Facility using methods described previously [73]. S1P/
dhS1P levels were assessed by ELISA (MyBioSource, 
MBS069092). Cell pellets were prepared according to the 
manufacturer’s instructions.
Assessment of apoptosis, cell viability, and 
proliferation
Jurkat cells (5 × 105 cells/ml) were treated with 
vehicle (70% PEG, 0.28% v/v final) or MP-A08 (5–15 
μM) for 5 or 24 h in RPMI medium containing 0.5% 
FBS. Analysis of TMRE staining and caspase 3 activity 
were carried out as described previously [74]. Annexin 
V staining was carried out according to manufacturer’s 
instructions (Annexin-V-Fluos, Roche) and analyzed by 
flow cytometry as described previously [74]. Generation 
of the Jurkat cell line stably expressing human Bcl-2α will 
be described elsewhere.
For population cell growth assays, adherent cancer 
cell lines (A549, BJ1, BJ7, MCF7 and MDA-MB-231) 
were seeded into 48-well plates (20,000 cells per well) 
or 96-well plates (15,000 cells per well) 8 h prior to 
treatment. Cells were then treated with MP-A08 or 
vehicle control (0.16% (v/v) DMSO/1.44% (v/v) ethanol) 
in DMEM containing 0.5% FBS, 1.2 mg/ml penicillin, 
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1.6 mg/ml streptomycin, and 1 mM HEPES. After 48 h 
relative viable cell numbers were determined using the 
MTS assay (Promega) according to the manufacturer’s 
protocol. Apoptosis in MEFs was assessed by DAPI 
staining as previously described [72].
Colony formation in soft agar
Assays were performed as previously described 
[75], with the following modifications. Cells were 
prepared in growth media containing 0.33% DMEM-
low-melting point agarose (Sigma) with either MP-A08 
or vehicle control. This was overlaid onto 0.5% DMEM-
low-melting agarose gel. After 14–21 days cells were 
analyzed by light microscopy and the number of colonies 
was quantified using ImageJ software [76].
Toxicity study of MP-A08 in NOD/SCID mice
MP-A08, dissolved in 70% (v/v) polyethylene 
glycol 400 (PEG 400), was administered at 50, 75 and 
100 mg/kg by intraperitoneal (i.p.) injection daily for 
2 weeks, as was vehicle control. Mice were weighed daily, 
and murine cell blood counts were determined after two 
weeks of treatment by a SYSMEX XE 2100 hematology 
analyzer. Tissue pathology of hematoxylin and eosin 
stained sections of the kidney, liver, heart and spleen of 
MP-A08 and vehicle-treated mice were assessed by an 
experienced veterinary pathologist.
A549 xenograft model
Mice were used with permission from the SA 
Pathology/Central Adelaide Local Health Network Animal 
Ethics Committee and experiments were performed under 
guidelines from the Australian code of practice for the 
care and use of animals for scientific purposes 7th Edition, 
2004.
A549 cells (5 × 106) were subcutaneously injected 
into the flanks of 6–8 week old female NOD/SCID mice. 
Tumor development was assessed daily and measured 
by caliper. Four weeks post engraftment when tumor 
sizes reached approximately 50–100 mm3, MP-A08 
was administered at 100 mg/kg six days a week for 
2 weeks, with daily measurement of tumors. Tumors 
were then excised and half was fixed in 10% formalin, 
paraffin embedded and sectioned. The remaining 
tumor was homogenized in a 1.5 ml tube using a pestle 
(Axygen) in 20 mM Tris-HCl (pH 7.4), 20% glycerol, 
1 mM β-mercaptoethanol, 1 mM EDTA, 1 mM sodium 
orthovanadate, 15 mM NaF, 0.5 mM deoxypyridoxine, 40 
mM β-glycerophosphate and protease inhibitor cocktail 
(Roche, EDTA-free) and tissue debris was pelleted by 
centrifugation at 13,000 × g for 15 mins at 4°C. S1P 
levels in samples were assessed by a S1P ELISA assay 
kit (Echelon; K-1900) according to manufacturers’ 
instructions. Apoptosis was examined by TUNEL 
staining using the Fluorescein in situ cell death detection 
kit (Roche) according the manufacturers’ instructions. 
For immunohistological analysis of visualization tumor 
tissue sections underwent a citrate buffer antigen retrieval 
process followed by blocking with 10% serum/PBS 
at room temperature for 60 min. Affinity purified goat 
polyclonal antibody to CD31/PECAM-1 (Santa Cruz; 
sc-1506) at 0.2 μg/ml was incubated overnight at 4°C 
followed by a 35 min incubation with biotinylated rabbit 
anti-goat antibody (1:500; Abcam) at room temperature. 
Sections were then incubated with VECTASTAIN 
Elite ABC Reagent at room temperature for 30 min, 
followed by peroxidase substrate solution. Sections were 
counterstained with Mayer’s haematoxylin, mounted using 
DPX and visualized on an Olympus BX45 microscope 
equipped with an XC10 camera. A single image was 
collected using the 10× objective which covered 30–60% 
of the total area of the section, and CD31-immunoreactive 
vessels were enumerated by a person blinded to the 
identity of the samples.
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